Appointments Focused on Innovation and Outreach
July 5, 2018 (York, UK) – Pharmerit International (Pharmerit), a leading provider of health economics and outcomes research (HEOR) and market access research services, has announced the appointment of two research professionals to its international team. Elisabeth Fenwick, PhD, MSc , will serve as Senior Director, Modeling and Meta-Analysis, and James Eaton, MSc, will serve as Senior Director, Strategic Market Access. Both individuals will serve the global company from their base in Pharmerit’s UK office.
“We welcome these two key additions to our global team,” said Stephanie Stephens, Executive Director and Business Development Lead, Pharmerit (York). “Elisabeth’s experience in developing decision analytic modeling and simulation methods will further support the innovative approach to research for which Pharmerit is recognized. James’ expertise in evidence synthesis, the preparation of global value and core reimbursement dossiers, and budget impact modeling will enhance our outreach and service to UK and global partners in pharmaceuticals and biotechnology. His insight into all stages of product development from trial design to the development of value propositions will ensure our position as a valued resource to the industry.”
Elisabeth Fenwick, PhD, MSc, Senior Director, Modeling and Meta-Analysis, has over 20 years of HEOR experience on a variety of projects in a wide range of disease areas, including oncology, respiratory conditions, infectious diseases, cardiology, ophthalmology, and orphan diseases. She has contributed to decision analytic modeling and simulation methods, probabilistic decision analytic modeling, and value of information analysis methods in the HEOR field. Elisabeth Fenwick holds a PhD and MSc in health economics from the University of York as well as an MSc in operations research from University of Southampton. She currently co-chairs the ISPOR task force assessing emerging good practices in value of information analysis for research decisions; she is also an associate editor for Medical Decision Makingand a member of the editorial board for Pharmacoeconomics. Prior to her consultancy career, Elisabeth spent over 15 years as an academic working at the University of York, McMaster University, and, most recently, University of Glasgow.
James Eaton, MSc, Senior Director, Strategic Market Access, has extensive expertise in the preparation of global value dossiers, core reimbursement dossiers, HEOR evidence generation plans, and cost-effectiveness models. He is accomplished in providing strategic insight into all stages of product development from trial design to the development of value propositions. James has prepared and directed health technology agency (HTA) submissions for NICE, SMC, NCPE, and the AWMSG, and has supported and participated in over 100 submissions to HTA agencies worldwide, including those in the Asia-Pacific region and South America. James Eaton holds a MSc in health economics from the University of York. Prior to his career as a health economist, he spent over 9 years in sales and marketing roles in the pharmaceutical industry.